Status:
COMPLETED
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
Lead Sponsor:
Mayo Clinic
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to develop a test for detection of pancreatic cancer by looking at the subject's DNA.
Detailed Description
Pancreatic juice collection is performed by intravenous injection of FDA approved synthetic human secretin (ChiRhoClin Inc., Burtonsville, MD) at a dose of 0.2 µg/kg will be administered while the end...
Eligibility Criteria
Inclusion
- Patients who are referred for the evaluation of pancreas cancer, pancreatic cystic neoplasm, and family history of pancreas cancer.
- International normalized ratio (INR) less than 1.5
- Platelet count \>50,000
Exclusion
- Any medical condition that preclude the patient from having a therapeutic procedure regardless of the Endoscopic ultrasound (EUS) finding
- Pregnant patients
Key Trial Info
Start Date :
January 11 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 10 2022
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT03404661
Start Date
January 11 2018
End Date
March 10 2022
Last Update
June 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224